These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22735949)

  • 1. Engineering of affibody molecules for therapy and diagnostics.
    Feldwisch J; Tolmachev V
    Methods Mol Biol; 2012; 899():103-26. PubMed ID: 22735949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold.
    Nygren PA
    FEBS J; 2008 Jun; 275(11):2668-76. PubMed ID: 18435759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.
    Löfblom J; Feldwisch J; Tolmachev V; Carlsson J; Ståhl S; Frejd FY
    FEBS Lett; 2010 Jun; 584(12):2670-80. PubMed ID: 20388508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of an optimized scaffold for affibody molecules.
    Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
    J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-idiotypic protein domains selected from protein A-based affibody libraries.
    Eklund M; Axelsson L; Uhlén M; Nygren PA
    Proteins; 2002 Aug; 48(3):454-62. PubMed ID: 12112671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
    Wållberg H; Löfdahl PK; Tschapalda K; Uhlén M; Tolmachev V; Nygren PK; Ståhl S
    Protein Expr Purif; 2011 Mar; 76(1):127-35. PubMed ID: 21029777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection and characterization of Affibody ligands to the transcription factor c-Jun.
    Lundberg E; Brismar H; Gräslund T
    Biotechnol Appl Biochem; 2009 Jan; 52(Pt 1):17-27. PubMed ID: 18260830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides.
    Grönwall C; Jonsson A; Lindström S; Gunneriusson E; Ståhl S; Herne N
    J Biotechnol; 2007 Jan; 128(1):162-83. PubMed ID: 17088007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity.
    Grimm S; Salahshour S; Nygren PÅ
    N Biotechnol; 2012 Jun; 29(5):534-42. PubMed ID: 22027369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules.
    Renberg B; Shiroyama I; Engfeldt T; Nygren PK; Karlström AE
    Anal Biochem; 2005 Jun; 341(2):334-43. PubMed ID: 15907880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro.
    Jonsson A; Wållberg H; Herne N; Ståhl S; Frejd FY
    Biotechnol Appl Biochem; 2009 Aug; 54(2):93-103. PubMed ID: 19545237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A native chemical ligation approach for combinatorial assembly of affibody molecules.
    Lindgren J; Ekblad C; Abrahmsén L; Eriksson Karlström A
    Chembiochem; 2012 May; 13(7):1024-31. PubMed ID: 22532524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
    Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
    Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.
    Friedman M; Nordberg E; Höidén-Guthenberg I; Brismar H; Adams GP; Nilsson FY; Carlsson J; Ståhl S
    Protein Eng Des Sel; 2007 Apr; 20(4):189-99. PubMed ID: 17452435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-affinity binding to staphylococcal protein A by an engineered dimeric Affibody molecule.
    Lindborg M; Dubnovitsky A; Olesen K; Björkman T; Abrahmsén L; Feldwisch J; Härd T
    Protein Eng Des Sel; 2013 Oct; 26(10):635-44. PubMed ID: 23924760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection and characterization of an HIV-1 gp120-binding affibody ligand.
    Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S
    Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for molecular recognition in an affibody:affibody complex.
    Lendel C; Dogan J; Härd T
    J Mol Biol; 2006 Jun; 359(5):1293-304. PubMed ID: 16750222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affibody-mediated transferrin depletion for proteomics applications.
    Grönwall C; Sjöberg A; Ramström M; Höidén-Guthenberg I; Hober S; Jonasson P; Ståhl S
    Biotechnol J; 2007 Nov; 2(11):1389-98. PubMed ID: 17639529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
    Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
    Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.